| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6008228 | HOFFMANN LA ROCHE | Pharmaceutical compositions containing proteinase inhibitors |
Jun, 2015
(8 years ago) | |
|
US6008228 (Pediatric) | HOFFMANN LA ROCHE | Pharmaceutical compositions containing proteinase inhibitors |
Dec, 2015
(8 years ago) | |
| US6352717 | HOFFMANN LA ROCHE | Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses |
Nov, 2019
(4 years ago) | |
|
US6352717 (Pediatric) | HOFFMANN LA ROCHE | Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses |
May, 2020
(3 years ago) | |
Fortovase is owned by Hoffmann La Roche.
Fortovase contains Saquinavir.
Fortovase has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Fortovase are:
- US6008228
- US6008228*PED
- US6352717
- US6352717*PED
Fortovase was authorised for market use on 07 November, 1997.
Fortovase is available in capsule;oral dosage forms.
The generics of Fortovase are possible to be released after 16 May, 2020.
Drugs and Companies using SAQUINAVIR ingredient
Market Authorisation Date: 07 November, 1997
Treatment: NA
Dosage: CAPSULE;ORAL
More Information on Dosage
FORTOVASE family patents
